



Goldline Pharmaceutical Limited

CIN.: U51397MH2004PLC147806

Date: 02/06/2026

To,
The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai - 400001.

Scrip Code: 544759, Scrip ID:GLPL,

Subject: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to be held on **Tuesday, June 09, 2026.**

Dear Sir / Ma'am,

Pursuant to Regulation 29 (1) (a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('**SEBI Listing Regulations**'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on **Tuesday, June 09, 2026**, at the Registered Office of the Company at 103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, India, 440015, inter-alia, to transact the following businesses:

Financial Results for half year and year ended 31st March, 2026:

1. The Standalone Audited Financial Results set out in compliance with applicable Accounting Standards for the half-year and year ended 31st March, 2026 together with Statement of Assets and Liabilities.

Further, the outcome of the aforesaid meeting shall be filed separately.

Kindly take this intimation on your record.

Yours faithfully,

For Goldline Pharmaceutical Limited

Ruchi Sanket Modi

Company Secretary cum Compliance Officer